[{"from": "human", "value": "What can you tell me about this molecule? [C][C][N][C][C][C][Ring1][=Branch1][C@H1][Branch1][Ring2][C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][N][C][=C][Branch1][Branch1][C][Ring1][=Branch1][=O][S][C][=C][Ring1][#Branch1]"}, {"from": "gpt", "value": "The molecule is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD). It is a partial agonist of the serotonin type 3 receptor (5-HT3). Serotonin is a neurotransmitter that is known to be involved in the control of the gastrointestinal (GI) system. Preclinical studies of DDP733 established the compound\u2019s prokinetic properties (the ability to promote the motility of the GI tract)."}]